HSBC Holdings’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-5,944
Closed -$239K – 2925
2026
Q1
$239K Buy
+5,944
New +$128K ﹤0.01% 2540
2025
Q4
– Sell
-15,025
Closed -$345K – 2921
2025
Q3
$345K Sell
15,025
-42,873
-74% -$1000K ﹤0.01% 2277
2025
Q2
$1M Buy
57,898
+32,899
+132% +$609K ﹤0.01% 1798
2025
Q1
$552K Sell
24,999
-102,829
-80% -$2.84M ﹤0.01% 2024
2024
Q4
$4.08M Buy
127,828
+9,341
+8% +$281K ﹤0.01% 1209
2024
Q3
$3.41M Buy
118,487
+83,563
+239% +$3.09M ﹤0.01% 1241
2024
Q2
$1.34M Sell
34,924
-63,626
-65% -$2.88M ﹤0.01% 1548
2024
Q1
$5.79M Buy
+98,550
New +$6.28M ﹤0.01% 1052
2023
Q4
– Sell
-50,544
Closed -$1.96M – 2716
2023
Q3
$1.96M Buy
+50,544
New +$2.22M ﹤0.01% 1459
2023
Q2
– Sell
-17,530
Closed -$1.17M – 2557
2023
Q1
$1.17M Buy
+17,530
New +$1.01M ﹤0.01% 1704
2022
Q3
– Sell
-10,887
Closed -$497K – 2919
2022
Q2
$497K Buy
10,887
+996
+10% +$45.4K ﹤0.01% 2337
2022
Q1
$504K Buy
9,891
+5,290
+115% +$234K ﹤0.01% 2415
2021
Q4
$219K Buy
+4,601
New +$181K ﹤0.01% 2988
2021
Q3
– Sell
-3,701
Closed -$236K – 2974
2021
Q2
$236K Buy
+3,701
New +$191K ﹤0.01% 2671
2020
Q3
– Sell
-7,580
Closed -$248K – 2714
2020
Q2
$248K Buy
+7,580
New +$243K ﹤0.01% 2225

Other funds holding APLS

HSBC Holdings's APLS Position: Q2 2026 in Review

HSBC Holdings sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5,944 shares — an estimated $239K sold.

HSBC Holdings first reported a position in APLS in Q2 2020 and held it in 15 quarters. The position peaked at $5.79M in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • HSBC Holdings reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • HSBC Holdings sold 5,944 Apellis Pharmaceuticals shares in Q2 2026, an estimated $239K.
  • HSBC Holdings first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 15 quarters.
  • HSBC Holdings's Apellis Pharmaceuticals position peaked at $5.79M in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.